WKN :358705
ASX RELEASE 21 January 2004
Important New US Patent Granted for BioSiliconTM
“Smart Drug Delivery”
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a further patent in the important US market.
US Patent No. 6,666,214 provides for a method of implanting an electronic device within a living animal or human body, wherein the device includes bioactive silicon and a method of delivering a drug to a living animal or human by placing the drug to be delivered on or within a bioactive silicon structure.
The Patent provides an important first step in the development of ‘smart’ drug delivery devices making use of the semi-conductor properties of silicon. pSiMedica is currently advancing development of its partnering strategy and continues to progress discussions with leading electronics and chip technology companies who have all expressed strong interest in the development of such devices.
pSivida Managing Director Gavin Rezos said,” This new US Patent is an important addition to our already strong IP portfolio. The patent will draw further attention in the US to the versatility of the BioSiliconTM technology platform and in particular to large value adding electronics and chip companies looking to develop ‘smart’ devices with potential applications in controlled drug delivery and diagnostics.”
This US patent follows 4 earlier patent grants in the key jurisdictions of the United Kingdom and United States and further strengthens pSiMedica’s healthcare claims for the BioSiliconTM technology.
The pSiMedica Intellectual Property portfolio consists of 17 patent families, 7 granted patents and over 70 patent applications. pSiMedica owns all of the Intellectual Property (royalty free) for the application of BioSiliconTM.
Products protected by patents and patent applications owned by pSiMedica include materials comprising bioactive, resorbable and biocompatible silicon that are of value in the fabrication of new generations of intelligent drug delivery devices, orthopaedic implants and intelligent diagnostic tools.
-ENDS-
Released by:
Josh Mann
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
joshuamann@psivida.com.au
NOTES TO EDITORS:
pSivida Limited
pSivida is an Australian-based biotechnology company committed to the biomedical applications of nano-technology and which has as its core focus the development and commercialisation of nano-structured porous silicon (BioSilicon™) in biocompatible and biodegradable forms for use in human and animal healthcare through its UK subsidiary pSiMedica Limited, and in conjunction with UK Government owned QinetiQ plc. As a true ‘platform technology’, BioSilicon™ has multiple potential applications across the high growth healthcare sector, including controlled drug delivery, tissue engineering, diagnostics and orthopaedics.
pSivida is listed on the Australian Stock Exchange (ASX Code: PSD). www.pSivida.com.au
ASX RELEASE 21 January 2004
Important New US Patent Granted for BioSiliconTM
“Smart Drug Delivery”
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a further patent in the important US market.
US Patent No. 6,666,214 provides for a method of implanting an electronic device within a living animal or human body, wherein the device includes bioactive silicon and a method of delivering a drug to a living animal or human by placing the drug to be delivered on or within a bioactive silicon structure.
The Patent provides an important first step in the development of ‘smart’ drug delivery devices making use of the semi-conductor properties of silicon. pSiMedica is currently advancing development of its partnering strategy and continues to progress discussions with leading electronics and chip technology companies who have all expressed strong interest in the development of such devices.
pSivida Managing Director Gavin Rezos said,” This new US Patent is an important addition to our already strong IP portfolio. The patent will draw further attention in the US to the versatility of the BioSiliconTM technology platform and in particular to large value adding electronics and chip companies looking to develop ‘smart’ devices with potential applications in controlled drug delivery and diagnostics.”
This US patent follows 4 earlier patent grants in the key jurisdictions of the United Kingdom and United States and further strengthens pSiMedica’s healthcare claims for the BioSiliconTM technology.
The pSiMedica Intellectual Property portfolio consists of 17 patent families, 7 granted patents and over 70 patent applications. pSiMedica owns all of the Intellectual Property (royalty free) for the application of BioSiliconTM.
Products protected by patents and patent applications owned by pSiMedica include materials comprising bioactive, resorbable and biocompatible silicon that are of value in the fabrication of new generations of intelligent drug delivery devices, orthopaedic implants and intelligent diagnostic tools.
-ENDS-
Released by:
Josh Mann
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
joshuamann@psivida.com.au
NOTES TO EDITORS:
pSivida Limited
pSivida is an Australian-based biotechnology company committed to the biomedical applications of nano-technology and which has as its core focus the development and commercialisation of nano-structured porous silicon (BioSilicon™) in biocompatible and biodegradable forms for use in human and animal healthcare through its UK subsidiary pSiMedica Limited, and in conjunction with UK Government owned QinetiQ plc. As a true ‘platform technology’, BioSilicon™ has multiple potential applications across the high growth healthcare sector, including controlled drug delivery, tissue engineering, diagnostics and orthopaedics.
pSivida is listed on the Australian Stock Exchange (ASX Code: PSD). www.pSivida.com.au
